Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

266 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Real-World Clinical Management of Patients with Primary Biliary Cholangitis-A Retrospective Multicenter Study from Germany.
Wilde AB, Lieb C, Leicht E, Greverath LM, Steinhagen LM, Wald de Chamorro N, Petersen J, Hofmann WP, Hinrichsen H, Heyne R, Berg T, Naumann U, Schwenzer J, Vermehren J, Geier A, Tacke F, Müller T. Wilde AB, et al. Among authors: naumann u. J Clin Med. 2021 Mar 4;10(5):1061. doi: 10.3390/jcm10051061. J Clin Med. 2021. PMID: 33806503 Free PMC article.
Treatment of naïve patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAA.
Heidrich B, Wiegand SB, Buggisch P, Hinrichsen H, Link R, Möller B, Böker KH, Teuber G, Klinker H, Zehnter E, Naumann U, Busch HW, Maasoumy B, Baum U, Hardtke S, Manns MP, Wedemeyer H, Petersen J, Cornberg M; HepNet Study Group. Heidrich B, et al. Among authors: naumann u. PLoS One. 2014 Oct 10;9(10):e108751. doi: 10.1371/journal.pone.0108751. eCollection 2014. PLoS One. 2014. PMID: 25302676 Free PMC article.
Performance and Value of IFN-Lambda3 and IFN-Lambda4 Genotyping in Patients with Chronic Hepatitis C (CHC) Genotype 2/3 in a Real World Setting.
Wiegand SB, Heidrich B, Susser S, Rogalska-Taranta M, Petersen J, Böker KH, Grigorian N, Link R, Naumann U, John C, Lueth S, Malfertheiner P, Manns MP, Wedemeyer H, Sarrazin C, Cornberg M. Wiegand SB, et al. Among authors: naumann u. PLoS One. 2015 Dec 23;10(12):e0145622. doi: 10.1371/journal.pone.0145622. eCollection 2015. PLoS One. 2015. PMID: 26699619 Free PMC article.
Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
Dietz J, Susser S, Vermehren J, Peiffer KH, Grammatikos G, Berger A, Ferenci P, Buti M, Müllhaupt B, Hunyady B, Hinrichsen H, Mauss S, Petersen J, Buggisch P, Felten G, Hüppe D, Knecht G, Lutz T, Schott E, Berg C, Spengler U, von Hahn T, Berg T, Zeuzem S, Sarrazin C; European HCV Resistance Study Group. Dietz J, et al. Gastroenterology. 2018 Mar;154(4):976-988.e4. doi: 10.1053/j.gastro.2017.11.007. Epub 2017 Nov 13. Gastroenterology. 2018. PMID: 29146520
Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral treatment.
Knop V, Hofmann WP, Buggisch P, Klinker H, Mauss S, Günther R, Hinrichsen H, Hüppe D, Pfeiffer-Vornkahl H, Simon KG, Berg T, Manns MP, Friedrich-Rust M; German Hepatitis C-Registry. Knop V, et al. J Viral Hepat. 2019 Feb;26(2):224-230. doi: 10.1111/jvh.13021. Epub 2018 Nov 8. J Viral Hepat. 2019. PMID: 30315694
Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of chronic hepatitis C infection: data from the German Hepatitis C-Registry.
Berg T, Naumann U, Stoehr A, Sick C, John C, Teuber G, Schiffelholz W, Mauss S, Lohmann K, König B, Pangerl A, Niederau C. Berg T, et al. Among authors: naumann u. Aliment Pharmacol Ther. 2019 Apr;49(8):1052-1059. doi: 10.1111/apt.15222. Epub 2019 Mar 15. Aliment Pharmacol Ther. 2019. PMID: 30874328
Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections.
Dietz J, Spengler U, Müllhaupt B, Schulze Zur Wiesch J, Piecha F, Mauss S, Seegers B, Hinrichsen H, Antoni C, Wietzke-Braun P, Peiffer KH, Berger A, Matschenz K, Buggisch P, Backhus J, Zizer E, Boettler T, Neumann-Haefelin C, Semela D, Stauber R, Berg T, Berg C, Zeuzem S, Vermehren J, Sarrazin C; European HCV Resistance Study Group. Dietz J, et al. Clin Gastroenterol Hepatol. 2021 Jan;19(1):195-198.e2. doi: 10.1016/j.cgh.2019.10.051. Epub 2019 Nov 6. Clin Gastroenterol Hepatol. 2021. PMID: 31706062 Free article.
Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).
Stein K, Stoehr A, Klinker H, Teuber G, Naumann U, John C, Heyne R, Serfert Y, Niederau C, Zeuzem S, Berg T, Wiegand J; German Hepatitis C-Registry. Stein K, et al. Among authors: naumann u. Eur J Gastroenterol Hepatol. 2022 Jan 1;34(1):76-83. doi: 10.1097/MEG.0000000000001923. Eur J Gastroenterol Hepatol. 2022. PMID: 32956186
266 results